Change Control: New SUPAC Guidance published
The U.S. Food and Drug Administration (FDA) has published a new draft Guidance for Industry: SUPAC - Manufacturing Equipment Addendum. The guidance document is being distributed for comment purposes.
The draft guidance combines and supersedes the following two Scale-up and Post-approval Changes (SUPAC) Guidances for industry:
- SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum
- SUPAC-SS Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum.
This draft SUPAC addendum, together with the SUPAC guidances, gives guidance to the manufacturer determining the documentation which needs to be submitted to FDA regarding manufacturing equipment changes. It lists various kinds of manufacturing equipment with the respective description and equipment classification and clarifies the types of processes being referenced.
What are Scale-up and Post-approval Changes (SUPAC) Guidance Documents? They give recommendations to the pharmaceutical manufacturer in case of changes with respect to:
- Composition and Ingredients
- Process and equipment
- Batch size
- Manufacturing site
Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance: www.regulations.gov.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years